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Abstract: Low and high plasma glutamine levels are associated with increased mortality. This study
aimed to measure glutamine levels in critically ill patients admitted to the intensive care unit (ICU),
correlate the glutamine values with clinical outcomes, and identify proxy indicators of abnormal
glutamine levels. Patients were enrolled from three ICUs in South Africa, provided they met the
inclusion criteria. Clinical and biochemical data were collected. Plasma glutamine was categorized
as low (<420 µmol/L), normal (420–700 µmol/L), or high (>700 µmol/L). Three hundred and thirty
patients (median age 46.8 years, 56.4% male) were enrolled (median APACHE II score) 18.0 and
SOFA) score 7.0). On admission, 58.5% had low (median 299.5 µmol/L) and 14.2% high (median
898.9 µmol/L) plasma glutamine levels. Patients with a diagnosis of polytrauma and sepsis on
ICU admission presented with the lowest, and those with liver failure had the highest glutamine
levels. Admission low plasma glutamine was associated with higher APACHE II scores (p = 0.003),
SOFA scores (p = 0.003), C-reactive protein (CRP) values (p < 0.001), serum urea (p = 0.008), and
serum creatinine (p = 0.023) and lower serum albumin (p < 0.001). Low plasma glutamine was also
associated with requiring mechanical ventilation and receiving nutritional support. However, it was
not significantly associated with length of stay or mortality. ROC curve analysis revealed a CRP
threshold value of 87.9 mg/L to be indicative of low plasma glutamine levels (area under the curve
(AUC) 0.7, p < 0.001). Fifty-nine percent of ICU patients had low plasma glutamine on admission,
with significant differences found between diagnostic groupings. Markers of infection and disease
severity were significant indicators of low plasma glutamine.
Keywords: plasma glutamine; clinical outcome; critically ill adult patients
1. Introduction
Immunonutrition refers to the administration of nutrients to modulate the immune system to
improve the clinical outcome. These nutrients include glutamine, arginine, omega-3 fatty acids, and a
host of antioxidants [1]. Of these, glutamine is the most studied supplement. Numerous meta-analyses
have reported on several systemic and clinical benefits attributed to glutamine supplementation,
including decreased systemic infections [2–9], decreased intensive care unit (ICU) and hospital
stay [2,4–7,9,10], decreased cost [11], and ultimately decreased mortality [3,6,7,10]. However, not all
studies have been positive, and evidence of harm has also been reported [12,13]. It should be noted
that the former two studies did not supplement glutamine according to the recommended indications
and added antioxidants and other immunonutrients.
The results of these trials clearly demonstrated that glutamine supplementation is not without
risk and that there should be clearer guidelines on which patients would benefit from glutamine
Nutrients 2020, 12, 402; doi:10.3390/nu12020402 www.mdpi.com/journal/nutrients
Nutrients 2020, 12, 402 2 of 15
supplementation, what is the suitable dosage, route, and duration of administration. In their publication
addressing the question “Where did we go wrong in our pursuit of knowledge regarding the role
of glutamine in the ICU?”, the authors of the REDOXS (Reducing deaths due to oxidative stress)
trial acknowledged that they assumed that all critically ill patients had low plasma glutamine levels
and would therefore benefit from high-dose supplementation [14]. More recent work on this topic
has questioned this assumption. In human subjects, a circulating plasma glutamine level above
420 µmol/L is regarded as normal [15]. Low plasma glutamine levels have been associated with
increased mortality [15–18], and similarly, high plasma levels (above 700 µmol/L) have also been
associated with increased mortality [15,16,19]. Thus, plasma glutamine levels may have a U-shaped
curve in their clinical response and effect on mortality [15,16]. As circulating plasma glutamine
levels are not routinely measured in most hospitals, it becomes important to identify potential proxy
indicators of abnormal glutamine levels. The latter could assist with the clinical decision on when to
provide and when to withhold glutamine supplementation.
The primary aim of this study was to establish baseline glutamine levels in critically ill patients on
admission to ICU with various clinical conditions and to correlate the values with clinical outcomes and
mortality. The secondary aim was to identify surrogate clinical and biochemical markers of glutamine
deficiency or elevated plasma glutamine levels.
2. Materials and Methods
2.1. Subjects and Study Design
This multi-center cohort study enrolled adult patients (>18 years old) admitted to the surgical and
medical ICU’s of 3 Hospitals in South Africa (Tygerberg Hospital, Cape Town; Wits Donald Gordon
Medical Centre (WDGMC), Johannesburg and Kimberley Hospital Complex, Kimberley) during the
period July 2016 until December 2018. Inclusion criteria were an expected ICU stay of ≥3 days and no
glutamine supplementation during the previous 14 days before admission
The sample size of 300 subjects was calculated based on the primary aim to determine the
proportion of patients with glutamine deficiency with a precision of 9%, 90% power, and a 95%
confidence interval. For sub-group analysis (e.g., glutamine deficient versus glutamine sufficient), a
minimum of 135 subjects were needed per group, using 90% power and 95% confidence interval.
In each of the three hospitals, subjects were stratified by disease category (medical versus surgical).
A minimum of 50 surgical and 50 medical ICU subjects were selected per hospital. The first 50 surgical
and 50 medical subjects that met the inclusion criteria per facility were approached for participation.
2.2. Measurements
Baseline data (as discussed below) were determined within 24 h of ICU admission and repeated
on day 7 (or on ICU discharge if discharged between day 3 and 7).
2.3. Anthropometric Measurements
Weight and height were recorded on admission to the ICU and weight measurement was repeated
weekly for the duration of hospital stay. Body mass index (BMI) (weight (kg)/height (m2)) was
calculated and interpreted according to acknowledged guidelines [20].
2.4. Clinical and Medical Parameters
Routine clinical information was recorded, including length of stay in the ICU and hospital,
medical/surgical diagnosis, disease severity indicators e.g., Acute Physiology, Age, Chronic Health
Evaluation Score (APACHE II) (score (on admission) and Sequential Organ Failure Assessment (SOFA)
score (on admission and on day 7), need for mechanical ventilation (during ICU stay), development of
complications that required medical intervention anytime during the period of hospitalization, and
mortality (during ICU stay and hospitalization).
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2.5. Dietary Intake
Nutritional support was provided to all subjects using standard operating protocols for each
hospital. Daily nutritional intake of subjects was recorded in detail, including glutamine content of
feeds and supplements.
2.6. Plasma Glutamine
For the determination of plasma glutamine levels, a 10 mL blood sample was taken at ICU
admission and again at day 7 (or on the day of discharge if earlier than day 7). All samples were
centrifuged within 30 min and stored at −80 ◦C until analyses, using Liquid Chromatography Mass
Spectrometry. This analysis was done at the Central Analytical Facilities of Stellenbosch University.
Plasma glutamine serum levels were categorized as low (<420 µmol/L), normal (420–700 µmol/L),
and high (>700 µmol/L) [15].
2.7. Data Analysis
Microsoft Excel (Microsoft, Redmond, WA, USA) was used to capture the data and STATISTICA
(version 13.4, 2018; StatSoft, Tulsa, OK, USA) was used to analyze the data.
For continuous normally distributed variables, means and standard deviations were used as
measures of central location and spread respectively and for ordinal or non-normal data medians
and inter-quartile ranges (IQR). Relationships between two continuous variables were analyzed with
regression analysis and the strength of the relationship measured with the Pearson correlation or with
Spearman correlation for non-normal or ordinal variables. The relationships between continuous
response variables and nominal input variables were analyzed using one-way analysis of variance
(ANOVA) for completely randomized designs or the Kruskal–Wallis test if the residuals were not
normally distributed. For repeated measures with k repetitions, repeated-measures ANOVA was used
with the compound symmetry assumption on correlations over time. For k = 2, paired t-tests were
used or Wilcoxon tests for non-normal data. Receiver-operating characteristic (ROC) curves were used
to determine the optimal cut-off value for continuous responses versus dichotomous nominal variables.
Nominal variables were compared using contingency tables and the likelihood ratio chi-square test.
A p-value less than 5% indicated statistical significance in hypothesis testing. Missing data were not
replaced or imputed.
2.8. Ethical Principles
The study was approved by the Health Research Ethics Committees, Stellenbosch University and
University of the Witwatersrand (N14/08/114 and M170981, respectively). We also received approval
and permission to conduct the study from all three hospitals.
The study was carried out following the rules of the Declaration of Helsinki of 1975, revised in
2013. All subjects provided voluntary informed consent before participation in the study and could
withdraw at any time.
3. Results
A total of 330 subjects, 56.4% males, with a median age of 46.8 (IQR: 32.0–60.2) years participated.
(Table 1).
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Table 1. Demographic and clinical data on admission.
Variables
Unit
n Percentage (%)
Gender (n = 330)
Male 186 56.4
Female 144 43.6
Disease category (n = 330)
Medical 147 47.6
Surgical 173 52.4
Primary diagnosis (n = 330)
Sepsis 118 35.8
Polytrauma 62 18.8
Gastrointestinal oncology 42 12.7
Liver failure 28 8.5
Renal failure 24 7.3
Neurologic pathology 20 6.1
Respiratory failure 20 6.1
Cardiac pathology 9 2.7
Vascular 7 2.1
Mechanical ventilation on admission (n
= 330)
Yes 223 67.6
No 107 32.4
HIV positive (n = 250)
Yes 45 18.0
No 205 82.0
Tuberculosis positive (n = 181)
Yes 9 5.0
No 172 95.0
BMI, categories (kg/m2) (n = 328)
Underweight (<18.5 kg/m2) 14 4.3
Normal weight (18.5–24.9 kg/m2) 126 38.4
Overweight (25.0–29.9 kg/m2) 106 32.3
Obese (30.0–39.9 kg/m2) 82 25
Mean ± SD Median (IQR)
Age (years) 47.4 ± 16.6 46.8 (32.0–60.2)
Illness severity indicators
APACHE II score (Admission) (n = 330) 18.6 ± 8.6 18.0 (11.0–25.0)
SOFA score (Admission) (n = 330) 7.1 ± 3.8 7.0 (4.0–10.0)
Length of stay (days) (n = 330)
ICU 9.5 ± 8.7 7.0 (4.0–11.0)
Hospital 18.6 ± 14.9 14.0 (8.0–26.0)
HIV: Human Immunodeficiency Virus; ICU: Intensive care unit; BMI: Body mass index; APACHE: Acute Physiology,
Age, Chronic Health Evaluation Score; SOFA: Sequential organ Failure Assessment Score; SD: Standard deviation;
IQR: Inter quartile range.
3.1. Medical Data
An even distribution was found between medical and surgical diagnostic groups. Primary
diagnosis of sepsis dominated (35.8%), followed by polytrauma (18.8%). A relatively small percentage
Nutrients 2020, 12, 402 5 of 15
of subjects were HIV positive (18.0% of those for whom the status was available), with an even smaller
group with microbiologically proven tuberculosis (5.0% of those for whom the status was available).
The majority were mechanically ventilated (67.2%) (Table 1).
On admission, the median APACHE II score was 18.0 and the median SOFA score was 7.0. Day 7
median SOFA score was 3.0 (IQR: 1.0–7.0). The total duration of ICU stay was half that of hospital stay
(7.0 versus 14.0 days respectively). (Table 1). A quarter of all subjects died during the study (n = 78/316,
24.6%), and 54 of the deaths occurred during the first seven days.
3.2. Anthropometry
A median BMI of 25.7 kg/m2 was reported for the group (IQR: 22.9–29.9 kg/m2). Underweight
was present in 4.3% and overweight/obesity (BMI ≥ 25 kg/m2) in 57.3% of subjects. (Table 1).
3.3. Dietary Intake
The majority of subjects (n = 251, 76.1%) received nutritional support during the first seven
days. Of those, enteral nutritional supplements formed the largest group (n = 195, 77.7%), followed
by combination therapy of enteral and parenteral nutrition (n = 29, 11.6%) and parenteral nutrition
only (n = 27, 10.8%). For those receiving nutrition support, the mean energy intake during the first
seven days of ICU stay in ICU was 941.0 ± 688.3 kcal (median 1027.3 kcal, IQR: 212.8–1484.9 kcal).
This amounted to a mean of 12.6 ± 9.5 kcal/kg body weight per day. The mean protein intake was
44.2 ± 33.2 g (median 46.3 g, IQR: 10.7–70.1 g), amounting to 0.59 ± 0.5 g/kg body weight per day.
It should be noted that some subjects also received fluid diets and oral nutritional supplements.
However, because the intake of these fluids was inconsistent and not well charted, we did not consider
this in our calculations. A total of 45 subjects received glutamine as part of the parenteral nutrition
support. Taken as an average intake for all subjects receiving nutrition support, this was calculated as
1.23 ± 3.8 g per day (0.015 ± 0.05 g/kg body weight per day).
3.4. Biochemical Data
Even though an improvement was noted for most parameters, all values remained abnormal by
day 7 (Table 2).
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Table 2. Biochemical results at admission and discharge.
Biochemical
Variable
Normal
Range Unit
Admission Day 7/Discharge
n n
Albumin
(g/L) 35–52
Mean ± SD
Median
IQR
25.8 ± 7.7
26.0
21.0–31.0
318
25.0 ± 13.9
24.0
19.0–29.0
280
Urea
(mmol/L) 2.6–7.0
Mean ± SD
Median
IQR
11.9 ± 16.6
6.9
4.5–14.6
324
12.7 ± 12.7
7.8
4.5–14.1
289
Creatinine
(µmol/L) 60–100
Mean ± SD
Median
IQR
206.7 ± 290.4
103.0
68.0–197.5
324
167.5 ± 218.9
72.0
55.0–147.0
289
Total
bilirubin
(µmol/L)
0–21
Mean ± SD
Median
IQR
25.1 ± 47.1
11.0
7.0–3.0
322
23.2 ± 44.3
10.0
6.0–20.0
281
AST (u/L) 8–20
Mean ± SD
Median
IQR
289.9 ± 1105.7
53.0
28.0–153.0
321
84.3 ± 127.1
47.5
29.0–83.0
278
ALT (u/L) 5–40
Mean ± SD
Median
IQR
195.4 ± 675.3
34.0
19.0–87.0
322
98.6 ± 155.7
49.0
20.0–104.0
279
LDH (U/L) 140–280
Mean ± SD
Median
IQR
671.5 ± 1167.1
385.0
269.0–604.0
303
453.9 ± 332.7
379.0
256.0–517.0
265
CRP (mg/L) <10
Mean ± SD
Median
IQR
150.1 ± 133.9
117.0
35.5–251.0
322
122.6 ± 139.2
90.0
46.0–173.2
287
AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; LDH: Lactate dehydrogenase; CRP: C-reactive
protein; SD: Standard Deviation.
3.5. Plasma Glutamine
On admission, the mean plasma glutamine concentration was 464.9 ± 344.1 µmol/L (median
382.2, IQR: 280.7–572.2 µmol/L). More than half of the subjects (n = 193/330, 58.5%) had low plasma
glutamine levels (<420 µmol/L). High plasma glutamine (>700 µmol/L) was found in 14.2% (n = 47/330)
of subjects. The mean plasma glutamine on day 7 was 509.8 ± 543.9 µmol/L (median 418.9, IQR:
323.7–562.2 µmol/L). Expressed as a percentage of those that entered the study, 40.6% (n = 134/330)
had low plasma glutamine levels on day 7, while 11.5% (n = 38/330) fell in the high plasma glutamine
category. The proportion of subjects in the normal glutamine category increased slightly from 27.3%
(n = 90/330) at admission to 29.1% (n = 96/330) on day 7. (Figure 1). No discharge (day 7) glutamine
samples were obtained for 18.8% (n = 62/330) of subjects.
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Figure 1. Plasma glutamine categories for admission and day 7.
The admission plasma glutamine concentrations for each of the primary diagnostic categories
are displayed in Figure 2 by means of boxplots. The lowest median values were recorded for the
polytrauma group (326.8 µmol/L; IQR: 249.8–424.7 µmol/L), followed by sepsis (351.8 µmol/L; IQR:
278.28–467.5 µmol/L). Significant differences were found between polytrauma with respiratory failure
(p = 0.028) and liver failure (p = 0.024, Kruskal–Wallis tests).Nutrients 2020, 12, x FOR PEER REVIEW 7 of 14 
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Figure 2. Boxplots indicating plasma glutamine levels per diagnostic group. GI—Gastrointestinal.
More than half of subjects with polytrauma (74.2%), sepsis (69.5%), cardiac pathology (55.6%),
neurologic pathology (55.0%), and renal failure (54.2%) presented with low plasma glutamine on
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admission. On the other hand, 28.9% of subjects with liver failure and 25.0% of those with respiratory
failure presented with a high plasma glutamine value.
3.6. Changes in Glutamine Status from Admission to Discharge
A paired t-test was used to determine the difference in mean glutamine concentrations (day
7/discharge (509.8 ± 543.9) − admission (466.9 ± 333.9 µmol/L)) (n = 268). A difference of 42.9 ± 542.7
µmol/L (p = 0.211) indicated a slight increase in circulating glutamine levels over the first seven days.
When excluding the 45 subjects that received parenteral nutrition (PN) glutamine supplementation,
the mean glutamine difference over time was 17.02 µmol/L (p = 0.505).
3.7. Associations between Plasma Glutamine and Various Clinical Outcomes
Baseline plasma glutamine were weakly negatively correlated with CRP on admission (r = −0.287,
p < 0.0001), serum urea on admission (r = −0.124, p = 0.026), and weakly positively correlated with
total bilirubin on admission (r = 0.262, p < 0.001), serum ALT on admission (r = 0.119, p = 0.032), and
SOFA day 7 (r = 0.133, p = 0.024). (Spearman correlations).
Tables 3 and 4 compare subjects with a low admission glutamine (<420 µmol/L) and those with
a normal or elevated glutamine level (≥420 µmol/L) in terms of clinical and biochemical outcomes.
Subjects with low glutamine on admission were more likely to have a positive tuberculosis status
(Chi2 = 4.75, p = 0.029), be on mechanical ventilation (Chi2 = 12.65, p < 0.001), and require nutritional
support (Chi2 = 5.74, p= 0.016). A low admission plasma glutamine (<420µmol/L) was also significantly
associated with higher APACHE II scores (p = 0.003), higher SOFA scores on admission (p = 0.003),
higher CRP values on admission (p < 0.001) and day 7 (p = 0.002), higher serum urea on admission
(p = 0.008) and day 7 (p = 0.028), and higher serum creatinine on admission (p = 0.023) and day 7
(p = 0.006). It was also associated with lower serum albumin on admission (p < 0.001).
This study did not find significant associations between admission plasma glutamine and length
of stay (ICU or hospital), number of complications, or mortality during the hospitalization period.
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Table 3. Clinical outcomes in subjects with a low admission plasma glutamine (<420 µmol/L) and those with a normal or elevated glutamine level (≥420 µmol/L).
Parameter Glutamine <420 µmol/L (n = 193) Glutamine ≥420 µmol/L (n = 137) p-Value
Disease category (n (%))
Medical 90 (57.3) 67 (42.7)
0.683; Chi2 = 0.16 *
Surgical 103 (59.5) 70 (40.5)
RVD status (n = 250) (n (%))
Positive 31 (68.9) 14 (31.1)
0.06; Chi2 = 3.36 *
Negative 111 (54.2) 94 (45.8)
Tuberculosis status (n = 181) (n (%))
Positive 8 (88.9) 1 (11.1)
0.029; Chi2 = 4.75 *
Negative 94 (54.7) 78 (45.3)
Mechanical ventilation on admission (n = 324) (n (%))
Yes 145 (65.6) 76 (34.4)
<0.001; Chi2 = 12.65 *
No 46 (44.7) 57 (55.3)
Severity of disease (mean ± SD; median; IQR)
APACHE II score (n = 327) 19.8 ± 8.9; 20.0; 12.0–26.0 16.9 ± 7.9; 16.0; 10.0–22.0 0.003 ***
SOFA score Admission (n = 326) 7.6 ± 3.8; 7.0; 5.0–11.0 6.3 ± 3.6; 6.0; 3.0–8.0 0.003 ***
SOFA score Day 7 (n = 291) 4.8 ± 4.2; 4.0; 1.5–7.0 4.5 ± 4.3; 3.0; 1.0–6.0 0.573 ***
Length of stay (days) (mean ± SD; median; IQR)
ICU 9.5 ± 6.9; 7.0; 4.0–11.0 9.5 ± 10.7; 6.0; 4.0–11.0 0.966 **
Hospital 19.7 ± 15.5; 15.0; 8.0–28.0 17.1 ± 14.1; 13.0; 8.0–23.0 0.125 **
Number of complications (n = 305) (mean ± SD; median; IQR) 2.8 ± 3.1; 2.0; 1.0–4.0 2.5 ± 3.1; 2.0; 1.0–3.0 0.460 **
Mortality during hospitalization (n = 316) (n (%))
Yes 50 (64.1) 28 (35.9)
0.305; Chi2 = 1.05 *
No 137 (57.6) 101 (42.4)
Nutrition support (n (%))
Yes 156 (62.2) 95 (37.8)
0.016; Chi2 = 5.74 *
No 37 (46.8) 42 (53.2)
Statistical analysis used: * Maximum-likelihood (ML)-Chi square test; ** t-test for independent samples; *** ANOVA—analysis of variance; RVD: Retroviral disease; APACHE:
Acute Physiology, Age, Chronic Health Evaluation Score; SOFA: Sequential organ Failure Assessment Score; ICU: Intensive care unit AST: Aspartate aminotransferase; ALT: Alanine
aminotransferase; LDH: Lactate dehydrogenase; CRP: C-reactive protein. Statistically significant values (p < 0.05) are indicated in bold.
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Table 4. Biochemical outcomes (admission values) in subjects with a low admission plasma glutamine (<420 µmol/L) and those with a normal or elevated glutamine
level (≥420 µmol/L).
Parameter Unit
Baseline Data Discharge/Day 7 data
Glutamine <420 µmol/L
(n = 193)
Glutamine ≥420 µmol/L
(n = 137)
Total (n)
p-Value
Glutamine <420 µmol/L
(n = 193)
Glutamine ≥420 µmol/L
(n = 137)
Total (n)
p-Value
Glutamine (µmol/l)
Mean ± SD 280.5 ± 93.9 724.6 ± 397.3
n = 330
<0.001 *
419.1 ± 230.9 630.5 ± 772.1
n = 268
<0.001 *
Median 299.50 617.20 383.1 484.7
IQR 218.60–352.70 497.15–815.96 293.3–482.8 383.3–642.5
Albumin (g/L)
Mean ± SD 24.3 ± 7.5 28.0 ± 7.5
n = 318
<0.001 *
24.1 ± 17.5 26.2 ± 6.8
n = 280
0.208 *
Median 24.0 29.0 23.0 26.0
IQR 20.0–30.0 22.0–33.0 18.0–27.0 22.0–31.0
Urea (mmol/L)
Mean ± SD 13.9 ± 20.4 8.9 ± 7.9
n = 324
0.008 *
14.1 ± 12.9 10.8 ± 12.1
n = 289
0.028 *
Median 8.0 6.4 8.4 6.9
IQR 5.0–16.3 3.6–11.2 4.4–21.5 4.5–11.1
Creatinine
(µmol/L)
Mean ± SD 237.4 ± 341.6 162.8 ± 187.4
n = 324
0.023 *
197.9 ± 250.9 125.9 ± 157.2
n = 289
0.006 *
Median 111.0 93.0 74.0 69.5
IQR 70.0–250.0 62.0–141.0 56.0–229.0 54.0–107.0
Total bilirubin
(µmol/L)
Mean ± SD 20.9 ± 41.5 31.1 ± 53.7
n = 322
0.054 *
18.9 ± 38.8 29.0 ± 50.8
n = 281
0.059 *
Median 11.0 12.0 10.0 10.0
IQR 7.0–20.0 6.0–27.0 6.0–18.0 6.0–22.0
AST (u/L)
Mean ± SD 271.4 ± 1186.2 316.3 ± 981.1
n = 321
0.721 *
94.2 ± 154.8 70.9 ± 73.3
n = 278
0.132 *
Median 61.0 44.0 46.0 52.0
IQR 31.0–158.0 25.0–129.5 28.5–85.0 31.0–78.0
ALT (u/L)
Mean ± SD 144.8 ± 455.6 267.4 ± 896.9
n=322
0.108 *
90.8 ± 130.9 109.2 ± 184.3
n = 279
0.332 *
Median 34.0 34.0 43.0 56.0
IQR 19.0–82.0 19.0–93.0 19.0–96.0 24.0–111.0
LDH (u/L)
Mean ± SD 728.8 ± 1208.1 586.5 ± 1102.9
n = 303
0.298 *
493.1 ± 361.2 402.9 ± 284.9
n = 265
0.029 *
Median 432.0 327.5 398.5 316.0
IQR 293.0–648.0 244.0–546.0 290.0–573.0 230.0–491.0
CRP (mg/L)
Mean ± SD 190.1 ± 135.9 93.3 ± 108.2
n = 322
<0.001 *
144.3 ± 164.5 93.2 ± 87.1
n = 287
0.002 *
Median 172.0 53.0 114.5 72.6
IQR 67.0–300.0 13.0–125.0 56.0–187.0 29.9–135.9
Statistical analysis used: * t-test for independent samples; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; LDH: Lactate dehydrogenase; CRP: C-reactive protein.
Statistically significant values (p < 0.05) are indicated in bold.
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Receiver-operating characteristic (ROC) curves were used to determine which parameters
(admission APACHE II, SOFA, CRP, albumin, urea, creatinine, total bilirubin, AST, ALT, LDH,
and SOFA day 7) could be used to discriminate between low and sufficient admission glutamine
levels. From these parameters, the only analysis with an area under the curve ≥0.7, was found for CRP.
The ROC curve analysis indicated a CRP threshold value of 87.95 mg/dL to be indicative of low plasma
glutamine (Sensitivity = 71%, Specificity = 66%, positive predictive value = 75%, negative predictive
value = 62%, AUC = 0.70, 95% CI: 0.65–0.76, p < 0.001). (Figure 3). Of those subjects with a CRP value
exceeding 87.95 mg/dL (n = 179), 75.9% had plasma glutamine levels below 420 µmol/L.
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A small proportion of subjects (n = 47, 14.2%) fell in the high serum glutamine category on
admission. The mean glutamine concentration for this group was 1067.9 ± 521.2 µmol/L (median
898.9 µmol/L and IQR: 815.8–1088.3 µmol/L). Subjects with high glutamine levels were more likely
to be in the medical ward (Chi2 = 4.40, p = 0.036); had a significantly shorter hospital length of stay
(p = 0.04); and presented with significantly lower CRP values (p = 0.003). No significant associations
were found between high glutamine levels on admission and indicators of illness severity (SOFA and
APACHE II scores) or mortality. However, due to the small number of subjects in the high glutamine
category, the power to detect these associations was weak.
4. Discussion
This study aimed to determine the circulating plasma glutamine levels of critically ill subjects
on admission to three ICUs in South Africa. The average glutamine concentration was 464.9 µmol/L,
ranging from a minimum of 34.2 to a maximum level of 3380 µmol/L. More than half (59%) of
the subjects had glutamine deficiency and this correlated significantly with biochemical markers of
infection/inflammation (CRP level) and illness severity (SOFA and APACHE II scores).
The average plasma glutamine level in this study compares well to those reported in the literature
of similar patient groups, ranging from an average level of 420–497 µmol/L [15–17,21,22]. The average
age of the subjects was 47 years, which is similar to another South African study [22], but younger than
most other studies, which reported average ages of 59 years [15], 64 years [16], 68 years [21], and 74
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years [17]. The majority of subjects had a primary ICU admission diagnosis of sepsis, followed by
polytrauma and gastrointestinal oncology cases. The overall study mortality was 24%, with most of
the deaths occurring in the ICU.
Although patients did not receive routine glutamine supplementation during their ICU admission,
a small number of subjects received parenteral feeds containing glutamine at the discretion of the
treating physician. On average, we estimated that the glutamine supplements only amounted to
0.015 g/kg glutamine per day, which is unlikely to have affected the results of this observational study.
The prevalence of low plasma glutamine was 59% at baseline, and by day 7, 50% of subjects still
had a low plasma glutamine level. Using similar cut-off values to define glutamine deficiency, our
results are consistent with some of the highest reported figures. The prevalence of glutamine deficiency
in studies from The Netherlands ranged between 65% [23], 55% [21], and 31% [17]; a Swedish study
reported 44% deficiency [15]; a study from Japan reported a prevalence of 33% [16] and from South
Africa a prevalence of 38% was reported [22].
Significant clinical differences were found in circulating plasma glutamine levels according to
diagnostic category, with polytrauma subjects having the lowest levels, followed by patients with
sepsis. Those with liver failure had the highest mean glutamine values. Oudemans-van Straaten
et al. [17] also reported low glutamine levels with a narrow range for the sepsis group, although the
patients with sepsis in their study also had some outliers. Other groups have also reported on liver
failure patients having elevated glutamine levels [16], with Helling et al. [24] reporting a correlation
between plasma glutamine levels and severity of liver disease. The former group proposed that liver
glutamine uptake is reduced in cases of liver damage, resulting in raised plasma levels [16].
A low baseline glutamine level was associated with biochemical markers of sepsis (higher CRP
and lower albumin values) and injury severity (higher APACHE II and SOFA scores). Contradictory
findings are reported in the literature with injury severity indicators not strongly associated with
circulating glutamine in some cases [15,16] and positively associated in other cases [23]. The correlation
with markers of infection and inflammation has been confirmed by others, with lower plasma glutamine
levels found to be associated with lower albumin levels [17,18], higher CRP levels [18,22], and higher
circulating IL-1β and IL-6 levels [18]. In some studies, low glutamine levels were also associated with
renal impairment, but this was not confirmed in other studies [16]. Based on the results of the REDOXS
trial, harmful outcomes were reported in the subgroup of patients with baseline renal dysfunction who
received glutamine or antioxidant supplements [25]. This suggests the potential danger of routine
glutamine supplementation in patients with renal dysfunction without prior assessment of plasma
levels. Although it was not reported what proportion of this subgroup of patients in the REDOXS
study had glutamine deficiency at baseline, 31% of the total study population had glutamine deficiency
and 15% had supra-normal levels. Plasma glutamine levels were only tested on a subgroup of the
overall study population (66 of the total 1223) [12]. In our study, biochemical indicators of hepatic
dysfunction (raised bilirubin, AST, and ALT levels) were associated with elevated serum glutamine
levels. Similar findings have been reported by others [16,24].
We noted that patients with a low baseline glutamine had a higher ICU mortality, but this
association was not significant. Again, contradictory findings are reported in the literature, with
no strong link between glutamine levels and mortality [26], mortality associated with low baseline
glutamine levels [17,18], or mortality associated with either low or high glutamine levels [15,16].
Using the predictors of a low plasma glutamine, we determined cut-off values to differentiate
between a low and sufficient glutamine status. A CRP value exceeding 88 mg/dL was associated
with a low plasma glutamine status. This CRP value is similar to a previous study, which found a
cut-off CRP of 95.5 mg/dL (Specificity = 69%, Sensitivity = 62.2%, AUC = 0.759, 95% CI: 0.653–0.865),
p < 0.0001) [22]. We reported that two-thirds of subjects with CRP values exceeding this cut-off had low
plasma glutamine values, which can be regarded as a reasonably good indicator of inadequate levels.
This study did not set out to assess the effect of glutamine supplementation on clinical outcomes
and therefore we cannot comment on supplementation regimes. We describe the glutamine status of
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subjects on admission to and on day 7 of ICU stay and have determined associated clinical markers
of deficiency and subsequent outcomes. We found significant differences in circulating glutamine
levels between ICU admission diagnostic categories, ranging from deficient to supra-normal levels.
This highlights the danger of routine glutamine supplementation and strengthens the importance of
applying clinical judgement to every patient. Recently, the accuracy of a point-of-care instrument
to screen for hypoglutaminemia and hyperglutaminemia was confirmed [27]. Routine use of this
device might assist with clinical decision-making at the bedside. During periods of stress, glutamine
production may not be sufficient to keep up with demand [28,29] and during periods of glutamine
supplementation, endogenous glutamine production does not decrease [30,31]. This is associated
with the observation that glutamine deficiency is common in ICU patients, but also that routine
glutamine supplementation in ICU patients without documented clinical deficiency may result in
harmful outcomes [25]. For this reason, routine supplementation of glutamine to all critically ill patients
is not recommended by various Societies like ESPEN (European Society for Clinical Nutrition and
Metabolism) [32]; ASPEN (American Society for Parenteral and Enteral Nutrition) [33]; and the German
Nutrition Guidelines [34]. Although glutamine is thought to have an important role in critically ill
patients, the recognized contra-indications to glutamine supplementation must be adhered to, such as
the presence of multiple organ failure (especially renal and liver failure) [1,7,10,14,32,34] and patients
with septic shock requiring vasopressor support [1,7,10,34]. When supplementing with glutamine,
the dose should not exceed 0.5 g/kg body weight per day [7,10,14]; it should not be supplemented
during the early acute phase of critical illness [10,34]; it should be administered together with full
nutrition support [14] and the glutamine dose should not exceed 30% of the prescribed nitrogen
supply [7].
5. Conclusions
Nearly two-thirds (59%) of all critically ill medical and surgical subjects admitted to three South
African ICUs had a low plasma glutamine level on admission to ICU, and 14% had elevated glutamine
levels. Within each of the diagnostic categories, a range of low to high plasma glutamine values
were found. However, patients admitted with the diagnosis of polytrauma and sepsis had the lowest
glutamine values. Conversely, patients admitted with liver failure had the highest plasma glutamine
values. Biochemical markers of infection and inflammation (elevated CRP and decreased serum
albumin levels) and clinical scores of disease severity (elevated APACHE II and SOFA scores) were
significant indicators of low plasma glutamine levels. Even though these markers of disease severity
correlated significantly with low plasma glutamine levels, the latter were not associated with all
observed clinical outcomes (such as length of stay or mortality) apart from the need for mechanical
ventilation. These biochemical and clinical risk factors may help identify ICU patients at highest risk
for glutamine deficiency. The reasons for these low levels are complex and multifactorial, including
underlying pathology, inflammation, sepsis, nutritional state, and malignancy.
The data were gathered in three ICUs in South Africa that represent three different geographical
regions and included state and private institutions. We believe that it provides a good representation
of the patient profile in our country. The results are clinically relevant as they highlight the diagnostic
groupings most associated with a low glutamine status. It also identifies measures of disease severity
and clinical and biochemical markers that correlate significantly with hypoglutaminemia. Patients
meeting these criteria are at highest risk for glutamine deficiency and should be further investigated
with formal glutamine plasma levels. Future studies should investigate the effect of glutamine repletion
on clinical outcomes within specific diagnostic groupings.
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